BTIG analysts optimistic medtech will rebound in 2024 after ‘string of rough years’

Rising interest rates, fears about the impact of GLP-1 drugs and “choppy supply-chain dynamics” dragged on the industry this year, the analysts wrote.

By Nick Paul Taylor • Dec. 18, 2023

Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma

William Blair analysts said the product “should revolutionize how glaucoma is treated by addressing noncompliance with drops.”

By Nick Paul Taylor • Dec. 15, 2023

Explore the Trendline➔

Medical device industry continues to turn to AI

While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.

By MedTech Dive staff

Tandem completes US launch of revamped diabetes management platform

The platform, Tandem Source, combines the features of the company’s legacy t:connect offerings with new data reports.

By Nick Paul Taylor • Dec. 15, 2023

Medtronic snags first pulsed field ablation approval in US

The treatment for atrial fibrillation has gained attention as a safer alternative to radiofrequency and cryoablation. Boston Scientific and Johnson & Johnson are also pursuing the PFA market.

By Susan Kelly • Dec. 14, 2023

Resmed hails ‘significant victory’ as patent board rules in dispute with NYU

The decisions invalidate claims that NYU argued were infringed by Resmed’s sleep apnea devices.

By Nick Paul Taylor • Dec. 14, 2023

In wake of Philips recall, senators urge review of FDA medical device oversight

Sens. Richard Durbin and Richard Blumenthal said the sleep apnea device maker “did nothing” while patients suffered.

By Susan Kelly • Dec. 14, 2023

Integra to buy J&J’s Acclarent for $275M

Integra said the purchase, which includes a portfolio of balloon dilation products for the sinuses and eustachian tube, would make it a market leader in ENT procedures.

By Elise Reuter • Dec. 13, 2023

Zimvie’s collaboration with Brainlab delivers 510(k) win for spinal fixation system

Amid recent struggles in its spine unit, Zimvie has been expanding its Brainlab partnership.

By Nick Paul Taylor • Dec. 13, 2023

The FDA approved 2 renal denervation devices. There are still questions about who will benefit.

The devices from Recor and Medtronic are intended to treat high blood pressure. An advisory panel backed the former, but recommended against approval of the latter.

By Elise Reuter • Dec. 13, 2023

Activist investor takes stake in Nevro amid struggles to grow neuromodulation sales

Engaged Capital is opposed to Nevro going after acquisitions that may jeopardize its core business, Bloomberg reported Monday.

By Nick Paul Taylor • Dec. 12, 2023

Why heart device makers are investing in left atrial appendage closure

Medtronic and Johnson & Johnson are pursuing a market that leader Boston Scientific predicts could hit $6 billion by 2030.

By Susan Kelly • Dec. 12, 2023

Hologic promotes Essex Mitchell to COO

Mitchell joined Hologic as vice president of sales and commercial excellence for the GYN surgical division in 2017.

By Nick Paul Taylor • Dec. 11, 2023

Medtronic expands AI endoscopy partnership with Cosmo

The collaboration will focus on Cosmo Intelligent Medical Devices’ GI Genius module, which Medtronic distributes globally.

By Elise Reuter • Dec. 11, 2023

Advamed adds medical imaging division, names new board chair

The medtech association is bringing on staff from the Medical Imaging & Technology Alliance to lead the new division.

By Elise Reuter • Dec. 11, 2023

BD receives 510(k) clearance for fingerstick blood test sample collection device

The clearance positions BD and partner Babson Diagnostics to support blood collection from community sites such as pharmacies.

By Nick Paul Taylor • Dec. 8, 2023

Medtronic secures CE mark for rechargeable Percept deep brain stimulation device

The company plans to make the device available in Western Europe this month and “launch in additional regions based on local regulations.”

By Nick Paul Taylor • Updated Dec. 13, 2023

Medtronic scraps plans to buy insulin patch-pump maker EOFlow

Medtronic cited “multiple breaches” of the companies’ agreements. EOFlow has been embroiled in patent lawsuits with Insulet this year.

By Elise Reuter • Dec. 7, 2023

5 takeaways from J&J’s investor day

The company outlined its long-term growth expectations and confirmed that it has no plans to separate its medtech and pharma segments.

By Elise Reuter • Dec. 6, 2023

US hospitals forecast 9% capex growth to support elective procedure backlog: survey

The Baird survey of 38 health system CFOs forecasts that hospital capital spending growth in 2024 will slow from a 13% jump this year.

By Nick Paul Taylor • Dec. 6, 2023

J&J hernia mesh settlement prompts judge to dismiss more than 200 cases

The company and claimants in Georgia filed to dismiss cases related to Ethicon’s Physiomesh in late November. 

By Nick Paul Taylor • Dec. 6, 2023

Intuitive’s venture capital arm launches second investment fund

The $150 million fund will back early-stage companies focused on healthcare access, digital health, and precision diagnostics and interventions.

By Susan Kelly • Dec. 5, 2023

Laboratory trade group, providers oppose FDA’s lab developed test proposal

A CDRH spokesperson confirmed to MedTech Dive that a discrepancy in the submission system used for the proposed rule led to an initial overcount of public comments.

By Nick Paul Taylor • Updated Dec. 7, 2023

Baxter sends another safety notice about syringe infusion pump errors

The company shared “reinforced guidance” to mitigate the risk of underdosing and interruptions to treatment.

By Nick Paul Taylor • Updated Dec. 6, 2023

Nevro buys low back pain company Vyrsa for $40M

The company expects the acquisition to be revenue accretive starting in 2024.

By Elise Reuter • Dec. 4, 2023

Resmed’s new C-suite focused on growing sleep apnea device demand: analysts

After gaining market share during the Philips recall, Resmed can keep growing by stimulating demand through marketing initiatives and new products, William Blair analysts wrote.

By Nick Paul Taylor • Dec. 4, 2023